Sodium-Potassium ATPase Catalytic Subunit Alpha-2: A Promising Drug Target and Biomarker

Target Name: ATP1A2

NCBI ID: G477

ATP1A2

Sodium-Potassium ATPase Catalytic Subunit Alpha-2: A Promising Drug Target and Biomarker

Introduction

Sodium-potassium ATPase (S-ATPase) is a protein that plays a crucial role in generating ATP, the primary energy currency in the cell. It is a transmembrane protein that spans the membrane of all eukaryotic cells and is involved in the regulation of ion homeostasis, including the regulation of intracellular sodium and potassium levels. The S-ATPase is composed of two subunits, alpha-2 and alpha-3, which are responsible for the catalytic activity of the enzyme. In this article, we will focus on the S-ATPase catalytic subunit alpha-2 (ATP1A2) as a drug target and biomarker.

Drug Target and Biomarker Characterization

Sodium-potassium ATPase is a target of several anti-cancer drugs, including diuretics, which are drugs that increase urine production to remove excess fluid from the body. One of the mechanisms by which these drugs work is by inhibiting the activity of the S- ATPase, which results in the accumulation of intracellular sodium and potassium ions. By inhibiting the S-ATPase, these drugs can cause cells to die or undergo apoptosis, which is a natural mechanism of cell death that can lead to a reduction in cancer cell proliferation.

In addition to its potential as a drug target, S-ATPase has also been identified as a potential biomarker for cancer. The S-ATPase is a protein that is expressed in most tissues and cells, including those of cancer cells. Therefore, its levels can be used as an indicator of disease status, with higher levels of S-ATPase indicating a more aggressive cancer. This has led to the use of S-ATPase as a biomarker for various types of cancer, including breast, ovarian, and colorectal cancers.

Expression and localization of S-ATPase

S-ATPase is a transmembrane protein that is expressed in most tissues and cells. It is primarily localized to the outer mitochondrial membrane, where it is involved in the regulation of ion homeostasis. S-ATPase is composed of two subunits, alpha-2 and alpha-3, which are responsible for the catalytic activity of the enzyme. The alpha-2 subunit is the catalytic subunit, while the alpha-3 subunit is the structural subunit.

S-ATPase is involved in the regulation of several intracellular processes, including the regulation of sodium and potassium levels, as well as the production of ATP. It is a critical enzyme in the production of ATP, which is the primary energy currency of the cell . S-ATPase is also involved in the regulation of the levels of intracellular calcium ions, which are essential for various cellular processes, including muscle contractions and nerve function.

S-ATPase is expressed in most tissues and cells, including those of cancer cells. Its levels are often higher in cancer cells, which may reflect their increased energy demand. Therefore, the expression of S-ATPase is an attractive target for anti-cancer drugs that are designed to inhibit its activity.

Drugs that inhibit S-ATPase activity have been shown to be effective in various types of cancer. For example, the drug Colchicine has been shown to inhibit S-ATPase activity and is currently being investigated as a potential anti-cancer drug.Colchicine is a natural compound that has been used for centuries as a cancer treatment, and recent studies have suggested that it

Protein Name: ATPase Na+/K+ Transporting Subunit Alpha 2

Functions: This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium, providing the energy for active transport of various nutrients

The "ATP1A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP1A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets